Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews

Key Data Concepts:   

? These are the company names, stock quotes, topics, and entities related to this data.

000925 002014 002486 300322 China Shipbuilding Industry Group Power Citic Securities Fujian Funeng Guotai Junan Securities Huangshan Novel Huizhou Speed Wireless Technology Jiangsu Hengrui Medicine Nanjing Pharmaceutical Shanghai Challenge Textile Company Limited Unittec Xiamen Amoytop Biotech Xinjiang Sayram Modern Agriculture Zhejiang Huahai Pharmaceutical Arts, Culture, Entertainment, Media Witness Accounting, Audit Layoffs, Downsizing Management Annual, Special Corporate Meeting Annual Report Research, Development Health, Beauty Product Pharmaceutical Media Credit, Debt Market, Exchange Securities Stocks Cancer Epidemic Hospital Medicine Therapy Pet Product, Service Small, Medium Enterprise Social Media Oncology Health

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Home » News » Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews